Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Announces Reverse Stock Split

NEW YORK (GenomeWeb) – Molecular diagnostics firm Rosetta Genomics announced today that it will effect a 1-for-12 reverse stock split in order to help regain compliance with the Nasdaq Capital Market's listing requirements.

In October, the company disclosed that it had been notified that it failed to meet the Nasdaq's $1 minimum bid price requirement for continued listing on the exchange. Following the reverse stock split — which is set to take effect at the start of trading tomorrow — every 12 ordinary shares of Rosetta will be consolidated into one share. Immediately after the reverse stock split, Rosetta will have approximately 1.9 million shares issued and outstanding.

During midday trading, Rosetta's stock was down nearly 4 percent to $.43.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.